Tocilizumab (Actemra)
What studies of Tocilizumab (Actemra) found
At a glance, by condition
Preventing long COVID: D Little or no difference
Based on the strongest evidence, compared with another group, not randomised (very low certainty): 2 findings, all D.
2 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with Tocilizumab (Actemra) for preventing long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Tocilizumab (Actemra) · Preventing long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Preventing long COVID
Symptoms
Breathlessness1 study · 405 people received Tocilizumab (Actemra) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: risk of bias couldn't be judged for most results (ROBINS-I: no information); the change wasn't shown to be more than chance.
Compared with another group, not randomised405 in the study · 1 year after hospital discharge
No clear difference in breathlessness.
The evidence is very uncertain about the effect of tocilizumab (Actemra) on breathlessness later, when given during acute COVID. Little or no difference · very low certainty D
- Risk of bias couldn't be judged for most results (ROBINS-I: no information)
- The change wasn't shown to be more than chance
See the 1 study
-
- People in the study
- 405 in the study
- Dose
- —
- Outcome
- lung function parameters
- Effect
- no clear difference
- Risk of bias
ROBINS-I: No information
- Confounding
- Moderate. comparison group: propensity-score matching
conditional on their demographic and clinical variables
- Selection of participants
- Moderate. comparison group: propensity-score matching
Patients were selected by matching their individual propensity for receiving therapy with tocilizumab, conditional on their demographic and clinical variables.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- NI. missing data aren't reported
- Measurement of outcomes
- Moderate. administered or clinician-rated; assessors blinded: NI
- Selection of the reported result
- Moderate. a pre-specified secondary outcome
Daily life and health overall
Overall symptoms1 study · 405 people received Tocilizumab (Actemra) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: risk of bias couldn't be judged for most results (ROBINS-I: no information); the change wasn't shown to be more than chance.
Compared with another group, not randomised405 in the study · 1 year after hospital discharge
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of tocilizumab (Actemra) on overall symptoms later, when given during acute COVID. Little or no difference · very low certainty D
- Risk of bias couldn't be judged for most results (ROBINS-I: no information)
- The change wasn't shown to be more than chance
See the 1 study
-
- People in the study
- 405 in the study
- Dose
- —
- Outcome
- 1-year overall mortality
- Effect
- no clear difference
- Risk of bias
ROBINS-I: No information
- Confounding
- Moderate. comparison group: propensity-score matching
conditional on their demographic and clinical variables
- Selection of participants
- Moderate. comparison group: propensity-score matching
Patients were selected by matching their individual propensity for receiving therapy with tocilizumab, conditional on their demographic and clinical variables.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- NI. missing data aren't reported
- Measurement of outcomes
- Low. an objective measure
- Selection of the reported result
- Moderate. a pre-specified primary outcome
Studies of combinations
Outcomes that only studies of Tocilizumab (Actemra) given together with other treatments looked at. Shown, not graded: they can’t tell what Tocilizumab (Actemra) did alone.
Cognition (brain fog) Preventing long COVID
Combination: Corticosteroid pulses + Tocilizumab (Actemra)96 in the study
Long-term cognitive performance and its relation to anti-inflammatory therapy in a cohort of survivors of severe COVID-19. (2022): TMT-B/A T-score, worse.
Shown, not counted: Tocilizumab (Actemra) was given together with other treatments.
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
8 mg at the start
- 2Raise
Raised step by step in 1 of 1 studies
- 3Top dose
Most often 800 mg (1 of 1 studies)
Doses across 1 study
8 to 800 mg.
Each study’s dose, as printed
- 400–800 mg, 8 mg/kg, single dose Long-term cognitive performance and its relation to anti-inflammatory therapy in a cohort of survivors of severe COVID-19. (2022)
All papers
- Treatment of COVID-19 during the Acute Phase in Hospitalized Patients Decreases Post-Acute Sequelae of COVID-19.2023 · compared with another group · 2,716 in the study · 1,966 started · 1,966 with outcome data
Summary
This single-center prospective observational study asked whether treatments given during acute COVID-19 were associated with post-acute sequelae of SARS-CoV-2 (PASC). The cohort included 2716 subjects referred after hospitalization or from primary care; 416 died and 334 were lost during follow-up and were excluded, and 1966 patients were followed at a Post-COVID-19 Unit. Hospitalized patients received protocolized remdesivir (200 mg the first day and 100 mg/day for 5 days), dexamethasone (6 mg/day for 10 days), tocilizumab in worsening respiratory symptoms, or methylprednisolone for organizing pneumonia; outpatients received no therapy. Treatment groups were compared with patients not receiving each treatment, with duration of PASC symptoms measured. In moderate disease, remdesivir was associated with 109 vs. 262 days and in severe disease 187 vs. 284 days, reported as significantly shorter. Dexamethasone showed 133 vs. 271 days in moderate and 266 vs. 309 days in severe disease; significance was not reported in the recorded result. Tocilizumab and methylprednisolone were not associated with a reduction in duration of PASC symptoms. Harms and withdrawals due to harms were not reported. The authors state limitations including no control group, single-center early-pandemic data, no vaccination status, and possible overestimation from nonparticipants having milder symptoms.
- Long-term effect of tocilizumab on mortality, readmissions, persistent symptoms and lung function in SARS-CoV-2 patients 1 year after hospital discharge: A matched cohort study.2023 · compared with another group · 405 in the study
Summary
This retrospective observational matched cohort study examined patients with SARS-CoV-2 who were discharged from one hospital after surviving the first wave in March-April 2020. The authors aimed to evaluate the influence of tocilizumab on mortality throughout the year following discharge. A total of 405 patients were included in the mortality study, and 33.6 % were treated with tocilizumab; 390 patients were included in the assessment of persistent symptoms. Patients were selected by matching their individual propensity for receiving tocilizumab, conditional on demographic and clinical variables, and were compared with a control group. Follow-up was 1 year after hospital discharge. After propensity-score analysis, no association between tocilizumab use and 1-year overall mortality was found (HR= 2.05, 95 % CI: 0.21–19.98). No differences regarding persistent symptoms (OR= 1.01 95 %CI 0.57–1.79), nor lung function parameters (forced vital capacity: coefficient -0.16 95 %CI -0.45 to 0.14) were found throughout the year follow-up between control and tocilizumab group. The authors also stated that no association was found regarding readmissions. No harms data were reported.
- 392. The Impact of Therapeutic Interventions on Post-Acute Sequelae of SARS-CoV-2 (PASC) in COVID-19 Survivors: A Retrospective Analysis2023 · compared with another group
Summary
Researchers conducted a retrospective chart review at the reCOVer Clinic at Cleveland Clinic Foundation from March 2020 to November 2022. The paper defines PASC as persistent and debilitating symptoms continuing more than 28 days beyond the acute phase of COVID-19. They identified 57 patients deemed to have PASC and matched them with controls without PASC at a 1:1 ratio. The study reviewed multiple interventions given at the time of COVID-19 diagnosis; treatment duration was not reported. Among those who received nirmatrelvir-ritonavir, tocilizumab, remdesivir and dexamethasone, the paper reports no statistical differences in those that eventually developed PASC (p-values of 0.50, 0.74, 0.07 and 0.06, respectively). No harms or side effects are reported. The authors conclude that treatment alone at the time of COVID-19 diagnosis is not protective against the development of PASC and state that further studies are needed to identify other potential risk factors for PASC.
- Long-term cognitive performance and its relation to anti-inflammatory therapy in a cohort of survivors of severe COVID-19.2022 · combination: given with other treatments · 96 in the study
Summary
This prospective single-center longitudinal cohort study enrolled 96 consecutive adult patients who survived an ICU admission for severe COVID-19 at Radboud University Medical Center, Nijmegen, The Netherlands. Cognitive tests were performed at a mean ± SD of 6.5 ± 1.3 months after ICU discharge. Patients were stratified by anti-inflammatory treatment: 28 received no anti-inflammatory treatment, 26 received dexamethasone (once daily 6 mg intravenous for ten consecutive days), and 42 received dexamethasone plus tocilizumab (single intravenous dose 400–800 mg, 8 mg/kg). Overall, 26 participants (27%) were classified as cognitively impaired; 5 patients (18%) in the no-treatment group, 7 patients (27%) in the dexamethasone group, and 14 (33%) in the dexamethasone and tocilizumab group (p = 0.361). The authors report that overall occurrence and severity of cognitive dysfunction were not affected by anti-inflammatory therapy. Patients who received both dexamethasone and tocilizumab performed significantly worse on the TMT B/A than patients without anti-inflammatory therapy (T-score 40.3 ± 13.5 vs 49.1 ± 9.3, p = 0.007). A one-way ANOVA on TMT-A showed a statistically significant between-group difference (p = 0.042), although post-hoc analyses with correction did not confirm this. No statistically significant differences were found in self-report questionnaires between treatments. Secondary infections occurred in 7 (25.0) patients with no anti-inflammatory treatment, 5 (19.2) with dexamethasone, and 9 (21.4) with dexamethasone and tocilizumab. The authors state limitations include recruitment from one hospital, possible overestimation of cognitive performance because the most fragile refused more often, minor baseline differences between groups, and small subgroups limiting statistical power.
- Preventive interventions for post Covid-19 condition: systematic review update2024 · systematic review · preprint
Summary
This systematic review update searched on February 9, 2024 and included 24 studies (5 randomized and 19 non-randomized), all among adults. It examined interventions given during acute or post-acute COVID-19 to prevent post COVID-19 condition (PCC). For convalescent plasma in outpatients (1 trial; N=882), the RR (95% CI) was 0.93 (0.77-1.12), with moderate certainty. For probiotics in outpatients (1 trial; N=69), RR was 0.32 (0.13-0.78), low certainty. For metformin in outpatients (1 trial; N=450), RR was 0.50 (0.25-0.99), low certainty. For ivermectin in outpatients (1 trial; N=374), RR was 0.93 (0.50-1.71), low certainty. Therapeutic-dose heparin versus prophylactic-dose heparin in inpatients (1 trial; N=571) had RR 1.11 (0.94-1.30) for PCC, low certainty; for cognitive impairment RR was 0.49 (0.22 to 1.07), low certainty; and for HRQoL the MD was 0.12 (-3.22 to 3.46) [range 0-100], moderate certainty. In one trial, metformin (n=569) had no serious adverse events per group; fluvoxamine (n=319), ivermectin (n=406), metformin and fluvoxamine (n=336), and metformin and ivermectin (n=401) had no events in any comparison.